Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Preclinical development of T-cell receptor-engineered T-cell therapy targeting the 5T4 tumor antigen on renal cell carcinoma.

Xu Y, Morales AJ, Cargill MJ, Towlerton AMH, Coffey DG, Warren EH, Tykodi SS.

Cancer Immunol Immunother. 2019 Dec;68(12):1979-1993. doi: 10.1007/s00262-019-02419-4. Epub 2019 Nov 4.

PMID:
31686124
2.

Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.

Motzer RJ, Rini BI, McDermott DF, Arén Frontera O, Hammers HJ, Carducci MA, Salman P, Escudier B, Beuselinck B, Amin A, Porta C, George S, Neiman V, Bracarda S, Tykodi SS, Barthélémy P, Leibowitz-Amit R, Plimack ER, Oosting SF, Redman B, Melichar B, Powles T, Nathan P, Oudard S, Pook D, Choueiri TK, Donskov F, Grimm MO, Gurney H, Heng DYC, Kollmannsberger CK, Harrison MR, Tomita Y, Duran I, Grünwald V, McHenry MB, Mekan S, Tannir NM; CheckMate 214 investigators.

Lancet Oncol. 2019 Oct;20(10):1370-1385. doi: 10.1016/S1470-2045(19)30413-9. Epub 2019 Aug 16. Erratum in: Lancet Oncol. 2019 Aug 21;:.

PMID:
31427204
3.

Gene fusion analysis in renal cell carcinoma by FusionPlex RNA-sequencing and correlations of molecular findings with clinicopathological features.

Tretiakova MS, Wang W, Wu Y, Tykodi SS, True L, Liu YJ.

Genes Chromosomes Cancer. 2019 Aug 10. doi: 10.1002/gcc.22798. [Epub ahead of print]

PMID:
31400230
4.

Thyroid-Like Follicular Renal Cell Carcinoma Arising Within Benign Mixed Epithelial and Stromal Tumor.

Tretiakova MS, Kehr EL, Gore JL, Tykodi SS.

Int J Surg Pathol. 2019 Jul 25:1066896919863478. doi: 10.1177/1066896919863478. [Epub ahead of print]

PMID:
31342803
5.

Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIMSM registry.

Fishman M, Dutcher JP, Clark JI, Alva A, Miletello GP, Curti B, Agarwal N, Hauke R, Mahoney KM, Moon H, Treisman J, Tykodi SS, Daniels G, Morse MA, Wong MKK, Kaufman H, Gregory N, McDermott DF.

J Immunother Cancer. 2019 Mar 27;7(1):84. doi: 10.1186/s40425-019-0567-3.

6.

Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition.

Buchbinder EI, Dutcher JP, Daniels GA, Curti BD, Patel SP, Holtan SG, Miletello GP, Fishman MN, Gonzalez R, Clark JI, Richart JM, Lao CD, Tykodi SS, Silk AW, McDermott DF.

J Immunother Cancer. 2019 Feb 18;7(1):49. doi: 10.1186/s40425-019-0522-3.

7.

Clinical Utility of Chromosome Genomic Array Testing for Unclassified and Advanced-Stage Renal Cell Carcinomas.

Andeen NK, Qu X, Antic T, Tykodi SS, Fang M, Tretiakova MS.

Arch Pathol Lab Med. 2019 Apr;143(4):494-504. doi: 10.5858/arpa.2018-0104-OA. Epub 2018 Nov 1.

PMID:
30383394
8.

Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer.

Long GV, Tykodi SS, Schneider JG, Garbe C, Gravis G, Rashford M, Agrawal S, Grigoryeva E, Bello A, Roy A, Rollin L, Zhao X.

Ann Oncol. 2018 Nov 1;29(11):2208-2213. doi: 10.1093/annonc/mdy408.

9.

Patient-reported outcomes with nivolumab in advanced solid cancers.

Tykodi SS, Schadendorf D, Cella D, Reck M, Harrington K, Wagner S, Shaw JW.

Cancer Treat Rev. 2018 Nov;70:75-87. doi: 10.1016/j.ctrv.2018.08.001. Epub 2018 Aug 2. Review.

10.

Erratum to "CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma" [Eur Urol 2017;72:962-71].

Escudier B, Sharma P, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Gurney H, Donskov F, Peltola K, Wagstaff J, Gauler TC, Ueda T, Zhao H, Waxman IM, Motzer RJ; CheckMate 025 investigators.

Eur Urol. 2018 Apr;73(4):e116-e118. doi: 10.1016/j.eururo.2017.12.016. Epub 2018 Jan 3. No abstract available.

PMID:
29306512
11.

Comparative Effectiveness of Initial Surgery vs Initial Systemic Therapy for Metastatic Kidney Cancer in the Targeted Therapy Era: Analysis of a Population-based Cohort.

Macleod LC, Odisho AY, Tykodi SS, Holt SK, Harper JD, Gore JL.

Urology. 2018 Mar;113:146-152. doi: 10.1016/j.urology.2017.11.014. Epub 2017 Nov 23.

PMID:
29174942
12.

CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma.

Escudier B, Sharma P, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Gurney H, Donskov F, Peltola K, Wagstaff J, Gauler TC, Ueda T, Zhao H, Waxman IM, Motzer RJ; CheckMate 025 investigators.

Eur Urol. 2017 Dec;72(6):962-971. doi: 10.1016/j.eururo.2017.02.010. Epub 2017 Mar 3. Erratum in: Eur Urol. 2018 Jan 3;:.

PMID:
28262413
13.

Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression: A Subgroup Analysis of a Randomized Clinical Trial.

George S, Motzer RJ, Hammers HJ, Redman BG, Kuzel TM, Tykodi SS, Plimack ER, Jiang J, Waxman IM, Rini BI.

JAMA Oncol. 2016 Sep 1;2(9):1179-86. doi: 10.1001/jamaoncol.2016.0775.

14.

A Drug Interaction Between Cabozantinib and Warfarin in a Patient With Renal Cell Carcinoma.

Foxx-Lupo WT, Sing S, Alwan L, Tykodi SS.

Clin Genitourin Cancer. 2016 Feb;14(1):e119-21. doi: 10.1016/j.clgc.2015.09.015. Epub 2015 Oct 3. No abstract available.

PMID:
26549824
15.

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.

Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Choueiri TK, Gurney H, Donskov F, Bono P, Wagstaff J, Gauler TC, Ueda T, Tomita Y, Schutz FA, Kollmannsberger C, Larkin J, Ravaud A, Simon JS, Xu LA, Waxman IM, Sharma P; CheckMate 025 Investigators.

N Engl J Med. 2015 Nov 5;373(19):1803-13. doi: 10.1056/NEJMoa1510665. Epub 2015 Sep 25.

16.

Trends in Metastatic Kidney Cancer Survival From the Cytokine to the Targeted Therapy Era.

Macleod LC, Tykodi SS, Holt SK, Wright JL, Lin DW, Tretiakova MS, True LD, Gore JL.

Urology. 2015 Aug;86(2):262-8. doi: 10.1016/j.urology.2015.05.008. Epub 2015 Jul 18.

PMID:
26199164
17.

Systemic therapy of metastatic melanoma: on the road to cure.

Bhatia S, Tykodi SS, Lee SM, Thompson JA.

Oncology (Williston Park). 2015 Feb;29(2):126-35. Review.

18.

PD-1 as an emerging therapeutic target in renal cell carcinoma: current evidence.

Tykodi SS.

Onco Targets Ther. 2014 Jul 25;7:1349-59. doi: 10.2147/OTT.S48443. eCollection 2014. Review.

19.

Alterations of immune response of Non-Small Cell Lung Cancer with Azacytidine.

Wrangle J, Wang W, Koch A, Easwaran H, Mohammad HP, Vendetti F, Vancriekinge W, Demeyer T, Du Z, Parsana P, Rodgers K, Yen RW, Zahnow CA, Taube JM, Brahmer JR, Tykodi SS, Easton K, Carvajal RD, Jones PA, Laird PW, Weisenberger DJ, Tsai S, Juergens RA, Topalian SL, Rudin CM, Brock MV, Pardoll D, Baylin SB.

Oncotarget. 2013 Nov;4(11):2067-79.

20.

HLA-F and MHC-I open conformers cooperate in a MHC-I antigen cross-presentation pathway.

Goodridge JP, Lee N, Burian A, Pyo CW, Tykodi SS, Warren EH, Yee C, Riddell SR, Geraghty DE.

J Immunol. 2013 Aug 15;191(4):1567-77. doi: 10.4049/jimmunol.1300080. Epub 2013 Jul 12.

21.

Toward eliminating HLA class I expression to generate universal cells from allogeneic donors.

Torikai H, Reik A, Soldner F, Warren EH, Yuen C, Zhou Y, Crossland DL, Huls H, Littman N, Zhang Z, Tykodi SS, Kebriaei P, Lee DA, Miller JC, Rebar EJ, Holmes MC, Jaenisch R, Champlin RE, Gregory PD, Cooper LJ.

Blood. 2013 Aug 22;122(8):1341-9. doi: 10.1182/blood-2013-03-478255. Epub 2013 Jun 5.

22.

Progress and potential of immune checkpoint blockade for treating advanced renal cell carcinoma.

Tykodi SS.

Immunotherapy. 2013 Jun;5(6):607-19. doi: 10.2217/imt.13.39. Review.

PMID:
23725284
23.

CD8+ T-cell clones specific for the 5T4 antigen target renal cell carcinoma tumor-initiating cells in a murine xenograft model.

Tykodi SS, Satoh S, Deming JD, Chou J, Harrop R, Warren EH.

J Immunother. 2012 Sep;35(7):523-33. doi: 10.1097/CJI.0b013e318261d630.

24.

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.

Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM.

N Engl J Med. 2012 Jun 28;366(26):2455-65. doi: 10.1056/NEJMoa1200694. Epub 2012 Jun 2.

25.

Allogeneic hematopoietic cell transplantation for renal cell carcinoma: ten years after.

Tykodi SS, Sandmaier BM, Warren EH, Thompson JA.

Expert Opin Biol Ther. 2011 Jun;11(6):763-73. doi: 10.1517/14712598.2011.566855. Epub 2011 Mar 21. Review.

26.

Combining allogeneic immunotherapy with an mTOR inhibitor for advanced renal cell carcinoma.

Tykodi SS, Voong LN, Warren EH.

Bone Marrow Transplant. 2010 Aug;45(8):1360-2. doi: 10.1038/bmt.2009.338. Epub 2009 Dec 7. No abstract available.

27.

Treatment of metastatic melanoma: an overview.

Bhatia S, Tykodi SS, Thompson JA.

Oncology (Williston Park). 2009 May;23(6):488-96. Review.

28.

Development of modified vaccinia Ankara-5T4 as specific immunotherapy for advanced human cancer.

Tykodi SS, Thompson JA.

Expert Opin Biol Ther. 2008 Dec;8(12):1947-53. doi: 10.1517/14712590802567298 . Review.

29.

C19orf48 encodes a minor histocompatibility antigen recognized by CD8+ cytotoxic T cells from renal cell carcinoma patients.

Tykodi SS, Fujii N, Vigneron N, Lu SM, Mito JK, Miranda MX, Chou J, Voong LN, Thompson JA, Sandmaier BM, Cresswell P, Van den Eynde B, Riddell SR, Warren EH.

Clin Cancer Res. 2008 Aug 15;14(16):5260-9. doi: 10.1158/1078-0432.CCR-08-0028.

30.

An antigen produced by splicing of noncontiguous peptides in the reverse order.

Warren EH, Vigneron NJ, Gavin MA, Coulie PG, Stroobant V, Dalet A, Tykodi SS, Xuereb SM, Mito JK, Riddell SR, Van den Eynde BJ.

Science. 2006 Sep 8;313(5792):1444-7.

31.

Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: toxicity, clinical response, and immunological response to minor histocompatibility antigens.

Tykodi SS, Warren EH, Thompson JA, Riddell SR, Childs RW, Otterud BE, Leppert MF, Storb R, Sandmaier BM.

Clin Cancer Res. 2004 Dec 1;10(23):7799-811.

32.

T-cell therapy targeting minor histocompatibility Ags for the treatment of leukemia and renal-cell carcinoma.

Warren EH, Tykodi SS, Murata M, Sandmaier BM, Storb R, Jaffee E, Childs R, Thompson JA, Greenberg PD, Riddell SR.

Cytotherapy. 2002;4(5):441. Review. No abstract available.

PMID:
12473218
33.
34.

Partial activation of CD8+ T cells by a self-derived peptide.

Cao W, Tykodi SS, Esser MT, Braciale VL, Braciale TJ.

Nature. 1995 Nov 16;378(6554):295-8.

PMID:
7477351

Supplemental Content

Loading ...
Support Center